128 related articles for article (PubMed ID: 37407896)
1. Clinical Outcomes of Drug-eluting Beads Transarterial Chemoembolization for Unresectable Gastric Carcinoma.
Bi Y; Ren J; Han X
J Gastrointest Surg; 2023 Nov; 27(11):2577-2579. PubMed ID: 37407896
[No Abstract] [Full Text] [Related]
2. Clinical outcomes of doxorubicin-eluting CalliSpheres® beads-transarterial chemoembolization for unresectable or recurrent esophageal carcinoma.
Bi Y; Shi X; Ren J; Yi M; Han X; Song M
BMC Gastroenterol; 2021 May; 21(1):231. PubMed ID: 34020608
[TBL] [Abstract][Full Text] [Related]
3. Preliminary outcomes of raltitrexed eluting bead-transarterial chemoembolization using Callispheres® beads for gastrointestinal adenocarcinoma liver metastasis.
Bi Y; Jiao D; Wang Y; Han X; Ren J
World J Surg Oncol; 2022 Jul; 20(1):229. PubMed ID: 35821043
[TBL] [Abstract][Full Text] [Related]
4. Transarterial chemoembolization of unresectable renal cell carcinoma with doxorubicin-loaded CalliSpheres drug-eluting beads.
Bi Y; Shi X; Ren J; Yi M; Han X
Sci Rep; 2022 May; 12(1):8136. PubMed ID: 35581365
[TBL] [Abstract][Full Text] [Related]
5. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
Wu B; Zhou J; Ling G; Zhu D; Long Q
World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773
[TBL] [Abstract][Full Text] [Related]
6. Clinical Outcomes of Drug-Eluting Bead Transarterial Chemoembolization Loaded with Raltitrexed for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma.
Bi Y; Jiao D; Ren J; Han X
Can J Gastroenterol Hepatol; 2022; 2022():2602121. PubMed ID: 36051250
[TBL] [Abstract][Full Text] [Related]
7. Short-term efficacy and safety of callispheres drug-loaded microsphere embolization in primary hepatocellular carcinoma.
Li J; Wang N; Shi C; Liu Q; Song J; Ye X
J Cancer Res Ther; 2021 Jul; 17(3):733-739. PubMed ID: 34269307
[TBL] [Abstract][Full Text] [Related]
8. Callispheres® drug-eluting beads transarterial chemoembolization might be an efficient and safety down-staging therapy in unresectable liver cancer patients.
Peng N; Mao L; Tao Y; Xiao K; Yuan G; He S
World J Surg Oncol; 2022 Aug; 20(1):254. PubMed ID: 35941634
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of raltitrexed-eluting CalliSpheres
Sun Z; Jiao D; Fang Y; Liu Y; Xu K; Zhang C; Huang Y; Han X
Ther Adv Med Oncol; 2024; 16():17588359241229661. PubMed ID: 38362379
[TBL] [Abstract][Full Text] [Related]
10. Comparison of CalliSpheres
Shi Z; Wang D; Kang T; Yi R; Cui L; Jiang H
Radiol Oncol; 2023 Mar; 57(1):70-79. PubMed ID: 36794998
[TBL] [Abstract][Full Text] [Related]
11. Preliminary outcomes of DEB-TACE loaded with raltitrexed in the treatment of unresectable or recurrent hepatocellular carcinoma.
Bi Y; Wang Y; Zhang W; Lu H; Ren J; Han X
Cancer Imaging; 2023 Feb; 23(1):19. PubMed ID: 36814327
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, safety, and prognostic factors of drug-eluting beads transarterial chemoembolization using CalliSpheres in treating huge hepatocellular carcinoma patients.
Wang Z; Mu K; Lv Y; Zhao L; Li B; Hao Y; Wang N
Ir J Med Sci; 2022 Dec; 191(6):2493-2499. PubMed ID: 35064533
[TBL] [Abstract][Full Text] [Related]
13. A comparison between drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis of six randomized controlled trials.
Wang H; Cao C; Wei X; Shen K; Shu Y; Wan X; Sun J; Ren X; Dong Y; Liu Y; Zhai B
J Cancer Res Ther; 2020; 16(2):243-249. PubMed ID: 32474508
[TBL] [Abstract][Full Text] [Related]
14. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting.
Karalli A; Teiler J; Haji M; Seth E; Brismar TB; Wahlin S; Axelsson R; Stål P
Scand J Gastroenterol; 2019 Jul; 54(7):905-912. PubMed ID: 31287338
[No Abstract] [Full Text] [Related]
15. Assessment of efficacy and safety by CalliSpheres versus HepaSpheres for drug-eluting bead transarterial chemoembolization in unresectable large hepatocellular carcinoma patients.
Zhao G; Liu S; Chen S; Ren Z; Li C; Bian J; Wu J; Zhou J; Zhang Y
Drug Deliv; 2021 Dec; 28(1):1356-1362. PubMed ID: 34180755
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors for survival in patients with unresectable hepatocellular carcinoma undergoing chemoembolization with doxorubicin drug-eluting beads: a preliminary study.
Dhanasekaran R; Kooby DA; Staley CA; Kauh JS; Khanna V; Kim HS
HPB (Oxford); 2010 Apr; 12(3):174-80. PubMed ID: 20590884
[TBL] [Abstract][Full Text] [Related]
17. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC.
Prajapati HJ; Xing M; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
AJR Am J Roentgenol; 2014 Dec; 203(6):W706-14. PubMed ID: 25415737
[TBL] [Abstract][Full Text] [Related]
18. Irinotecan eluting beads-transarterial chemoembolization using Callispheres® microspheres is an effective and safe approach in treating unresectable colorectal cancer liver metastases.
Zhao G; Liu S; Zhang Y; Zhao T; Wang R; Bian J; Wu J; Zhou J
Ir J Med Sci; 2022 Jun; 191(3):1139-1145. PubMed ID: 34264426
[TBL] [Abstract][Full Text] [Related]
19. An investigation of efficacy, safety, and prognostic factors of drug-eluting beads-transarterial chemoembolization operation with CalliSpheres
Zhang X; Lin X; Qiu H; Peng Z
J Clin Lab Anal; 2019 Oct; 33(8):e22975. PubMed ID: 31328832
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety profile of drug-eluting beads transarterial chemoembolization by CalliSpheres® beads in Chinese hepatocellular carcinoma patients.
Zhou GH; Han J; Sun JH; Zhang YL; Zhou TY; Nie CH; Zhu TY; Chen SQ; Wang BQ; Yu ZN; Wang HL; Chen LM; Wang WL; Zheng SS
BMC Cancer; 2018 Jun; 18(1):644. PubMed ID: 29914435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
